These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The importance of screening for the MEN 1 syndrome: diagnostic results and clinical management. Lips CJ; Koppeschaar HP; Berends MJ; Jansen-Schillhorn van Veen JM; Struyvenberg A; Van Vroonhoven TJ Henry Ford Hosp Med J; 1992; 40(3-4):171-2. PubMed ID: 1362399 [No Abstract] [Full Text] [Related]
27. Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas. Williams JC; Stone D; Smith-Arica JR; Morris ID; Lowenstein PR; Castro MG Mol Ther; 2001 Dec; 4(6):593-602. PubMed ID: 11735344 [TBL] [Abstract][Full Text] [Related]
28. [Association of growth hormone and prolactin pituitary adenoma and parathyroid adenoma. Variety of polyendocrine adenomatosis]. Mollet E; Lonchampt F Nouv Presse Med; 1982 Nov; 11(48):3569. PubMed ID: 6130511 [No Abstract] [Full Text] [Related]
29. Hyperprolactinemia and prolactinomas. Mancini T; Casanueva FF; Giustina A Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731 [TBL] [Abstract][Full Text] [Related]
30. An overview of the epidemiology and genetics of acromegaly. Daly AF; Petrossians P; Beckers A J Endocrinol Invest; 2005; 28(11 Suppl International):67-9. PubMed ID: 16625848 [TBL] [Abstract][Full Text] [Related]
31. Growth hormone receptor mRNA expression in non-functioning and somatotroph pituitary adenomas: implications for growth hormone substitution therapy? Beuschlein F; Hancke K; Petrick M; Göbel H; Honegger J; Reincke M Exp Clin Endocrinol Diabetes; 2005 Apr; 113(4):214-8. PubMed ID: 15891957 [TBL] [Abstract][Full Text] [Related]
32. [Type I multiple endocrine neoplasia with prolactin-secreting tumor revealed by pituitary apoplexy (author's transl)]. Richard JL; Ribstein J; Bringer J; Pages M; Jaffiol C; Mirouze J Nouv Presse Med; 1981 Oct; 10(38):3149-52. PubMed ID: 6117057 [TBL] [Abstract][Full Text] [Related]
33. [Case of type I polyglandular syndrome associated with prolactinoma]. Krassowski J; Grzelec T Pol Tyg Lek; 1983 May; 38(18):565-7. PubMed ID: 6138760 [No Abstract] [Full Text] [Related]
34. [Tumor predisposition in endocrinology - from MEN to FIPA]. Jegodzinski L; Gebauer J Dtsch Med Wochenschr; 2024 Mar; 149(6):283-289. PubMed ID: 38412983 [TBL] [Abstract][Full Text] [Related]
35. The epidemiology of prolactinomas. Ciccarelli A; Daly AF; Beckers A Pituitary; 2005; 8(1):3-6. PubMed ID: 16411062 [TBL] [Abstract][Full Text] [Related]
36. Epidemiology and Management Challenges in Prolactinomas. Vroonen L; Daly AF; Beckers A Neuroendocrinology; 2019; 109(1):20-27. PubMed ID: 30731464 [TBL] [Abstract][Full Text] [Related]
37. Medical treatment of pituitary tumors. Sheeler LR Cleve Clin J Med; 1994; 61(2):99-100; quiz 162. PubMed ID: 7910789 [No Abstract] [Full Text] [Related]
38. [Differentiated therapy of acromegaly and prolactinomas]. Etzrodt H; Hetzel WD MMW Munch Med Wochenschr; 1982 Nov; 124(46):1029-30. PubMed ID: 6817112 [No Abstract] [Full Text] [Related]
39. [Multiple endocrine neoplasia]. Miyauchi A; Takai S Gan No Rinsho; 1989 Jan; Spec No():663-71. PubMed ID: 2563406 [No Abstract] [Full Text] [Related]